Skip to content
Angioedema News logo Newsletter
Newsletter
  • About angioedema
    What is angioedema?
    Types
    • Acquired angioedema
    • Hereditary angioedema
    • Idiopathic angioedema
    • Acute allergic angioedema
    • Drug-induced nonallergic angioedema
    Causes
    Diagnosis
    Symptoms
    Living with angioedema
    • Diet
  • Treatments
    Approved treatments
    Experimental treatments
  • Featured topics
    Taking action with HAE
    • HAE and advocacy
    • Next steps after an HAE diagnosis
    • Beyond swelling: Other HAE symptoms
    • Treatment and management of HAE attacks
    • Raising a child with HAE
    • HAE triggers and prevention plan
    • HAE and preventive treatment
    • Bracing for a diagnosis
    • HAE and stress
    • Angioedema and skin care
    • View all
    Navigating HAE
    • HAE genetics
    • HAE and factor XII
    • Managing HAE medications
    • HAE and women
    • Traveling with HAE
    • HAE awareness and advocacy
    • Talking to your doctor
    • Self-care tips for caregivers
    • Exercise and HAE
    • Gut health
  • News
  • Columns
    Dancing with Rare Disease — Natalie Sirota
    From the Caregiver’s HAErt — Danita LaShelle Jones
    Living Rare, Speaking Loud — Hollie Amadio
  • What can we help you find today?

Andembry (garadacimab-gxii) for hereditary angioedema

Last updated June 23, 2025, by Marisa Wexler, MS
✅ Fact-checked by Joana Carvalho, PhD

Indications
Administration
Clinical trials
Side effects

 

What is Andembry for hereditary angioedema?

Andembry (garadacimab-gxii) is an antibody therapy for people with hereditary angioedema (HAE) that’s approved as a prophylactic treatment to prevent swelling attacks.

The therapy is designed to inhibit activated factor XII (FXIIa), a clotting protein that, when active, sets off a chain of events that triggers swelling attacks in HAE patients. By blocking FXIIa, Andembry aims to stop this signaling chain of events and prevent swelling. Andembry is the first approved HAE treatment that works by specifically targeting FXIIa.

Developed by CSL Behring, the treatment is given via subcutaneous, or under-the-skin, injections that can be self-administered by patients or given by a caregiver after proper training.

Therapy snapshot

Brand name: Andembry
Chemical name: Garadacimab-gxii
Usage: Used to prevent swelling attacks in people with hereditary angioedema
Administration: Subcutaneous injection

 

Who can take Andembry?

A prophylactic therapy, Andembry is approved in the U.S. to prevent swelling attacks in adult and pediatric patients, ages 12 and older, with HAE. The therapy is also approved for the same indication in the European Union and other regions and countries worldwide.

Andembry’s U.S. prescribing information lists no contraindications to its use.

How is Andembry administered?

Andembry is administered by subcutaneous injections given every month. Injections may be self-administered by patients or given by caregivers who have received appropriate training from medical experts.

The therapy is available as a single-dose prefilled autoinjector or a single-dose prefilled syringe, each of which contains 200 mg of the Andembry’s active ingredient. On the first day of treatment, patients receive a loading dose of 400 mg, given as two injections of 200 mg each, with subsequent injections being given every month at a maintenance dose of 200 mg.

These subcutaneous injections can be administered into the thigh, abdomen, and upper arm; injections in the abdomen must be at least one inch away from the navel.

Andembry for hereditary angioedema

Andembry in clinical trials

Andembry’s U.S. approval was based on data from the Phase 3 VANGUARD clinical trial (NCT04656418), which tested the therapy against a placebo in 64 people with HAE types 1 or 2, ages 12 and older, who had experienced at least three swelling attacks in the three months before entering the trial. The results showed that, after six months:

  • the monthly HAE attack rate was 89.2% lower with Andembry compared with the placebo
  • monthly rates for attacks requiring on-demand treatment and for moderate or severe attacks were lower for patients on Andembry than for those on the placebo
  • nearly two-thirds (62%) of patients on Andembry were free from swelling attacks, whereas all patients on the placebo experienced swelling attacks during the study.

Most patients who completed VANGUARD joined others in an extension study (NCT04739059) that is assessing the long-term safety and efficacy of Andembry. Available data from the extension study showed Andembry had a favorable safety profile and continued providing protection against swelling attacks after a year or longer.

CSL also is sponsoring a Phase 3 trial (NCT05819775) to test Andembry in children ages 2-11 with HAE. The goal of this study is to evaluate the therapy’s safety, efficacy, and pharmacological properties in younger patients.

Common side effects of Andembry

The most common side effects of Andembry include:

  • cold-like symptoms (nasopharyngitis)
  • abdominal pain.

Angioedema News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Recent Posts

  • Navenibart continues to reduce HAE attacks in long-term trial
  • Adjusting eating habits to live better with HAE, other diagnoses
  • Deucrictibant benefits maintained as treatment for HAE: Trial data
  • FDA approves Andembry as preventive treatment for HAE
  • Voices for change in a village of rare disease advocates, part 2


Related articles

  1. The words 'clinical trials' are pictured in all capital letters, with a handful of oral medications at the top left corner and a heart monitor reading at the bottom right.
    June 26, 2025 News by Andrea Lobo

    Navenibart continues to reduce HAE attacks in long-term trial

  2. Banner for
    June 24, 2025 Columns by Natalie Sirota

    Adjusting eating habits to live better with HAE, other diagnoses

  3. A person makes a presentation at a conference.
    June 23, 2025 News by Steve Bryson, PhD

    Deucrictibant benefits maintained as treatment for HAE: Trial data

  4. The word APPROVED reads as a stamp.
    June 18, 2025 News by Margarida Maia, PhD

    FDA approves Andembry as preventive treatment for HAE

  5. Banner for Hollie Amadio's column
    June 17, 2025 Columns by Hollie Amadio

    Voices for change in a village of rare disease advocates, part 2

  6. Multiple hands are seen giving the thumbs-up sign from within a black circle.
    June 16, 2025 News by Andrea Lobo

    Orladeyo approved in Colombia to prevent HAE swelling attacks

Swipe left to view more
Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

This field is for validation purposes and should be left unchanged.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2013-2025 All rights reserved.